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Background: Global COVID-19 deaths reached at least 400,000 fatalities. Hydroxychloroquine is an 54 
antimalarial drug that elicit immunomodulatory effects and had shown in vitro antiviral effects against 55 
SRAS-CoV-2. This drug divided opinion worldwide in the medical community but also in the press, 56 
the general public and in public health policies. The aim of this systematic review and this meta-57 
analysis was to bring a new overview on this controversial drug and to assess whether 58 
hydroxychloroquine could reduce COVID-19 mortality risk in hospitalized patients.  59 
 60 
Methods and Findings: Pubmed, Web of Science, Cochrane Library, MedRxiv and grey literature 61 
were searched until 10 June 2020. Only studies of COVID-19 patients treated with 62 
hydroxychloroquine (with or without azithromycin) compared with a comparative standard care group 63 
and with full-text articles in English were included. Studies reporting effect sizes as Odds Ratios, 64 
Hazard Ratio and Relative Risk for mortality risk and the number of deaths per groups were included. 65 
This meta-analysis was conducted following PRISMA guidelines and registered on PROSPERO 66 
(Registration number: CRD42020190801). Independent extraction has been performed by two 67 
independent reviewers. Effect sizes were pooled using a random-effects model.  68 
 69 
The initial search leaded to 112 articles, from which 16 articles met our inclusion criteria. 15 studies 70 
were retained for association between hydroxychloroquine and COVID-19 survival including 15,081 71 
patients (8,072 patients in the hydroxychloroquine arm and 7,009 patients in the standard care arm 72 
with respectively, 1,578 deaths and 1,423 deaths). 6 studies were retained for hydroxychloroquine 73 
with azithromycin. Hydroxychloroquine was not significantly associated with mortality risk (pooled 74 
Relative Risk RR=0.82 (95% Confidence Interval: 0.62-1.07, I²=82, Pheterogeneity<0.01, n=15)) within 75 
hospitalized patients, nor in association with azithromycin (pooled Relative Risk RR=1.33 (95% CI: 76 
0.92-1.92, I²=75%, Pheterogeneity<0.01, n=6)), nor in the numerous subgroup analysis by study design, 77 
median age population, published studies (vs unpublished articles), level of bias risk. However, 78 
stratified analysis by continents, we found a significant decreased risk of mortality associated with 79 
hydroxychlroquine alone but not with azithromycin among European (RR= 0.62 (95%CI: 0.41-0.93, 80 
n=7)) and Asian studies (RR=0.36 (95%CI:0.18-0.73, n=1)), with heterogeneity detected across 81 
continent (Pheterogeneity between=0.003). These finding should be interpreted with caution since several 82 
included studies had a low quality of evidence with a small sample size, a lack of adjustment on 83 
potential confounders or selection and intervention biases.  84 
 85 
Conclusion: Our meta-analysis does not support the use of hydroxychloroquine with or without 86 
azithromycin to reduce COVID-19 mortality in hospitalized patients. It raises the question of the 87 
hydroxychloroquine use outside of clinical trial. Additional results from larger randomised controlled 88 
trials are needed 89 
 90 
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Introduction 108 
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On December 31, 2019, World Health Organization (WHO) identified in Wuhan (China) an unknown 109 
pneumonia caused by a new coronavirus, SARS-CoV-2. This new coronavirus rapidly spread around 110 
the world and on the 11th of March, the WHO declared it as a pandemic. By 17 June, 2020, WHO 111 
confirmed 8,006,427 cases and 436,899 deaths. 112 
 113 
Recent publications identified the in vitro antiviral activity against SARS-CoV-2 of 114 
hydroxychloroquine (HCQ), an aminoquinoline like chloroquine. HCQ appeared as a potential 115 
treatment for COVID-19 patients at low costs(1). HCQ is also used as antimalarial drug, for 116 
rheumatoid arthritis and for lupus. This drug was widely advertised by international press and the 117 
United States President(2). Three in vitro studies tested HCQ on VeroE6 cells infected by SARS-CoV-118 
2. This later suggested that HCQ decreased the viral replication with 50% inhibitory concentration 119 
(IC50) values of 2.2 µM (0.7 µg/mL) and 4.4 µM (1.4 µg/mL) in Maisonnasse et al. study, at 0.72 µM 120 
in Yao et al. study and between 4.51 – 12.96 µM for 50% maximal effective concentration (EC50) in 121 
Liu et al. study (1–3). Another study reported a synergistic effect of the HCQ with azithromycin (AZ) 122 
against SARS-CoV-2(6). The mechanism would be an acidification of the endosomes pH, and this pH 123 
modification would block the virus-endosome fusion (7). 124 
 125 
Hydroxychloroquine was also tested in a study where macaques were infected by SARS-CoV-2 and 126 
received either a high dose of hydroxychloroquine (90 mg/kg on day 1 then 45 mg/kg) either a low 127 
HCQ dose (30 mg/kg on day 1 then 15 mg/kg) (3). Hydroxychloroquine did not improve the time to 128 
viral clearance. Another study in preprint also reported that there is no evidence of efficacy for the 129 
drug hydroxychloroquine (6.5 mg/kg) against infection with SARS-CoV-2 in hamsters or macaque 130 
models(8). 131 
 132 
By June 17, about 132 trials have been referenced to test hydroxychloroquine for COVID-19 on 133 
ClinicalTrials.gov (9). Until today, most of the published studies on hydroxychloroquine with a 134 
comparative group (standard care) were observational and non-randomized with inconsistent results 135 
(10–16). This study is the first meta-analysis to pool adjusted relative risk and to include 16 studies. 136 
Previous meta-analysis on COVID-19 included a very limited number of studies and used unadjusted 137 
risk ratio (17–19). Thus, the aim of this meta-analysis was to provide a systematically quantitative 138 
assessment of the association between HCQ treatment (vs standard care) and COVID-19 survival risk 139 
among human trials and observational studies. 140 
  141 
 142 
Material and methods 143 
Data sources, search strategy 144 
Research question was: does hydroxychloroquine treatment (vs standard care) have an effect (positive 145 
or negative) on survival of patients with COVID-19? A search was performed via PubMed and Web of 146 
Science and Cochrane Review until 10 June 2020 with this string search: (COVID-19 OR SRAS-CoV-147 
2) AND (MORTALITY OR DEATH) AND (HYDROXYCHLOROQUINE OR HCQ) 148 
(Supplementary text S1). Given that the number of articles about hydroxychloroquine and COVID-19 149 
is rapidly growing, we also manually searched additional reference on MedRxiv preprint server and on 150 
google scholar. The language was limited to English. This meta-analysis was conducted following 151 
PRISMA statements in Supplementary text S2. This study has been recorded on the international 152 
database of prospectively registered systematic reviews, PROSPERO (Registration number: 153 
CRD42020190801). 154 
 155 
 156 
 157 
 158 
Criteria for study selection: 159 
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Inclusion criteria were 1) reports must contain original data with available risk estimates (Hazard 160 
Ration, Odds Ratios, Relative Risk and/or with data on the number of death in HCQ and control 161 
groups 2) all publication dates will be considered 3) publications in English language 4) comparative 162 
studies with a control group without hydroxychloroquine and 5) COVID-19 confirmed cases by RT-163 
PCR. Reviews and meta-analysis, commentaries, in vitro and in vivo studies were excluded. 164 
 165 
Data extraction  166 
Data extraction was performed by two investigators (Mr. T. Fiolet and Mr. Y. Mahamat-Saleh) who 167 
screened the titles and abstracts. Discrepancies were resolved by a third investigator (Dr. Anthony 168 
Guihur).  169 
The following data were extracted from each study: study design, publication date, location, number 170 
of participants (total, in treatment and control groups, doses when available, effect size (Hazard Ratio, 171 
Odds Ratio or Relative Risk) and 95% confidence intervals for reported risk estimates. Hazard Ratio 172 
(HR) refers to the ratio of hazards in the intervention group divided by those occurring in the control 173 
group. Hazard represents the instantaneous event rate, which means the probability that an individual 174 
would experience an event (e.g. death) at a particular given point in time after the intervention, 175 
assuming that this individual has survived to that particular point of time without experiencing any 176 
event. In contrast, Relative Risk (RR) and Odds Ratio (OR) does not take account of the timing of 177 
each event. RR and OR are similar when the event (death) is rare. The most adjusted effect size 178 
reflecting the greatest control of potential confounders was extracted.  179 
Three included studies did not report effect size for mortality risk (15,20,21). Thus we used the 180 
number of death per groups to calculate an unadjusted relative risk using metabin function in meta 181 
package in R Software (22). RR calculation is based on Cochrane Handbook for Systematic Reviews 182 
of Interventions formula RR = 
number of deaths in treatment group
number of participants in treatment group 
 number of deaths in control group
number of participants in control group
 (23) 183 
For all the other studies, reported adjusted OR, RR or HR were used. The quality of each study was 184 
assessed with ROBIN-I tool following Cochrane guidelines for non-randomized studies and with Rob2 185 
for randomized studies (24,25).  186 
 187 
Outcome 188 
The outcome is COVID-19 mortality.  189 
 190 
Statistical analysis 191 
Effect of HCQ alone and HCQ + AZ 192 
A primary meta-analysis was performed to assess the association between hydroxychloroquine alone 193 
(vs standard care) and risk of death. In a second time, the relationship between hydroxychloroquine 194 
associated with azithromycin and mortality was assessed. HRs, ORs and RRs were treated as 195 
equivalent measures of mortality risk. Pooled RRs were determined by using a random effect model 196 
with inverse variance weighting (DerSimonian-Laird method) (26). Significance was checked by Z-197 
test (p<0.05 was considered as significant).  198 
 199 
Heterogeneity was assessed by the Chi-square test and I² test. 30%<I²<60% was interpreted as 200 
moderate heterogeneity and I²>60 as high heterogeneity. Funnel plot was constructed to assess the 201 
publication bias. Begg's and Egger's test were conducted to assess the publication bias (7,27). RR or 202 
HR and their 95% confidence interval were used to assessed mortality risk.  203 
 204 
 205 
 206 
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Subgroup analysis 207 
Subgroup analyses were further conducted according to the quality assessment to explore the source of 208 
heterogeneity among observational studies. We performed  stratified analyses by continents, the type 209 
of article (peer-reviewed vs unpublished), the use of an adjustment on confounding factors (studies 210 
with RRunadjusted vs RRadjusted), the mean daily dose of hydroxychloroquine (continuous), the median 211 
population age across the studies (median age>63 years) and the level of bias risk identified with 212 
ROBIN-I (moderate/serious/critical) (24), the exclusion of studies with cancer and dialysis patients. 213 
Mean daily dose of hydroxychloroquine is a daily average between the loading dose and the 214 
maintenance doses. Additionally, influence analysis was conducted by omitting each study to find 215 
potential outliers (28). It is used to detect studies which influence the overall estimate of our meta-216 
analysis the most, omitting one study at a time (leave-one-out method). 217 
 218 
 219 
A two-sided p-value <0.05 was considered statistically significant. All analysis were conducted using 220 
R version 3.6.1 with meta package and robvis package (29). 221 
 222 
Results 223 
Literature Search 224 
After searching Pubmed and Web of Science, 105 results were identified. 7 articles from 225 
Medrxiv/Google Scholar were added. After screening the title and the abstract, only 9 articles about 226 
hydroxychloroquine and COVID-19 were included. 144 articles were excluded for not meeting the 227 
inclusion criteria. 16 articles were included for further consideration including 14 observational 228 
studies and one non-randomized trial and one unpublished randomized controlled trial (RCT): 15 229 
articles for HCQ (10–17,20,21,30–34) and 6 articles for HCQ+AZ (10,16,30,31,35,36). Flow chart is 230 
presented in Figure 1.  231 
 232 
 233 
Figure 1: Flow diagram of study selection process 234 
 235 
Study characteristics 236 
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This meta-analysis includes 8,072 patients in the hydroxychloroquine group and 7,009 patients in the 237 
standard care group with respectively 1,578 deaths and 1,423 deaths. Individual studies are described 238 
in Table 1. It appears that all the included studies were carried on hospitalized patients. No study 239 
meeting our inclusion criteria addressed the effect of HCQ on asymptomatic forms of COVID-19. 240 
Mean and median age of participants ranged from 53 to 72 across the studies. Studies were conducted 241 
in the USA (n=6) (13,16,20,30,31,36), in Spain (n=4) (14,15,33,35), in France (n=2) (11,21), in the 242 
UK (n=1)(37), in Italy (n=1) (32), in China (n=1) (12) and in 3 countries (USA, Canada and 243 
Spain)(10). 9 articles were published, and 4 articles were preprints. RECOVERY Trial data were 244 
reported by a press communication (34,37). Mean daily dose of hydroxychloroquine ranged from 333 245 
mg/j to 945 mg/j. 246 
 247 
 248 
 249 
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First 
Author 
Journal 
Type of 
study 
Country 
Number of 
deaths 
Number of 
participants 
Treatment 
Mean 
HCQ 
dose 
per day 
Agea 
(years) 
Patients 
Study 
quality 
Control HCQ Control HCQ 
Alberici et 
al(32), 2020 
Kidney 
International 
Observational, 
cohort 
Italy 
Not 
reported 
Not 
reported 
22 72 Not specified NA 
72 
(median) 
IQ=62-79 
Hospitalized 
patients with 
haemodialysis 
Critical 
Ayerbe et 
al(15), 2020 
Journal of 
Thrombosis 
and 
Thrombolysis 
Observational, 
cohort 
Spain 49 237 162 1857 Not specified NA 
67,57 
(mean) 
Hospitalized 
patients 
Serious 
Barbosa 
Joshua et 
al(20), 2020 
Unpublished 
Observational, 
cohort 
USA 1 2 21 17 
800 mg for 2 
days then 200-
400mg for 3-4 
days 
600 
62.7 
(mean) 
SD=15.1 
Hospitalized 
patients 
(mild/moderate 
symptoms) 
Critical 
Geleris et 
al(13), 2020 
NEJM 
Observational, 
cohort 
USA 75 157 565 811 
1200mg at day 
1 then 400mg 
for 4 days 
560 
From <40 to 
>80 
Hospitalized 
patients 
(moderate/severe 
symptoms) 
Moderate 
Ip et al(31), 
2020 
PrePrint 
Observational, 
cohort 
USA 115 432 598 1914 
800mg at day 1 
then 400mg on 
day 2-5 (80%) 
400 
64 (median) 
IQ=52-76 
Hospitalized 
patients (44% 
moderate/severe 
symptoms) 
Moderate 
Kuderer et 
al(10), 2020 
The Lancet 
Observational, 
cohort 
USA 
Canada 
Spain 
41 11 486 89 Not specified NA 
66 (median) 
IQ=57-76 
Hospitalized 
patients with who 
have a current or 
past diagnosis of 
cancer 
Moderate 
Magagnoli et 
al(30), 2020 
Clinical 
Advances 
Observational, 
cohort 
USA 37 38 395 198 
Median HCQ 
dose: 
400mg/day 
Median 
HCQ+AZ 
dose: 422.2 
mg/day 
400 
70 (median) 
IQ=60-75 
Hospitalized 
patients 
Serious 
Mahevas et 
al(11), 2020 
BMJ 
Observational, 
cohort 
France 8 9 89 84 600mg/day 600 
60 (median) 
IQ=52-68 
Hospitalized 
patients with 
covid-19 
Moderate 
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pneumonia who 
require oxygen: 
Membrillo et 
al(14), 2020 
PréPrint 
Observational, 
cohort 
Spain 21 27 43 123 
Loading dose 
of 800 mg + 
400 mg in 
following days 
(ten days for 
moderate 
cases) 
440 
HCQ: 61.5 
No HCQ: 
68.7 (mean) 
Hospitalized 
patients 
Serious 
Philippe 
Gautret et 
al(21), 2020 
International 
Journal of 
Antimicrobial 
Agents 
Non-
randomised 
controlled 
trial 
France 0 1 16 26 
A maintenance 
dose of 600 
mg/day 
600 
45,1 (mean) 
SD=22 
Hospitalized 
patients (mild 
symptoms) 
Critical 
RECOVERY 
TRIAL 
Unpublished 
Randomized 
controlled 
trial 
UK 736 396 3132 1542 
A loading dose 
of 2400mg at 
day 1, then 
800mg/day for 
10 days 
945 Not specified 
Hospitalized 
patients 
Not 
applicable 
Rogado et 
al(35), 2020 
Clinical and 
Translational 
Oncology 
Observational, 
cohort 
Spain 
Not 
reported 
Not 
reported 
8 18 Not specified NA 
71 (median) 
Range:34-90 
Hospitalized 
patients 
(64% severe 
cases) 
Critical 
Rosenberg 
et al(16), 
2020 
JAMA 
Observational, 
cohort 
USA 28 54 221 271 
400mg then 
200-400mg at 
2nd 
prescription 
then 200-
400mg at 3rd 
333 63 (median) 
Hospitalized 
patients 
Moderate 
Sanchez-
Alvarez et 
al(33), 2020 
Nefrología 
Observational, 
cohort 
Spain 32 166 53 322 Not specified NA 
71 
SD=15 
(85%) required 
hospital 
admission, 8% 
in intensive care 
units, with 
haemodialysis 
Serious 
Singh et 
al(36), 2020 
PrePrint 
Observational, 
cohort 
USA 104 109 910 910 Not specified NA 
62 
SD=17 
Hospitalized 
patients 
Serious 
Yu et al(12), Science Observational, China 238 9 502 48 400mg during NA 68 (median) Critically ill Serious 
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2020 China Life 
Sciences 
cohort 7-10 days IQ: 59-77 patients 
Table 1 (continued): Characteristics of studies included in the meta-analysis for COVID-19 mortality 
IQ=Interquartile range, SD=Standard Deviation, HCQ=Hydroxychloroquine, AZ=Azithromycine, NA=Not available 
 
 
First 
Author 
Effect size reported in each 
studyb 
Adjustments Treatment Control 
Alberici et 
al(32), 2020 
OR=0,44 [0,16-1,24] Not adjusted HCQ alone 
Other antiviral 
and antibiotic 
were 
administered 
Ayerbe et 
al(15), 2020 
RRcalculated=0,422 [0,325-0,546] Not adjusted HCQ alone 
Other antiviral 
and antibiotic 
were 
administered 
Barbosa 
Joshua et 
al(20), 2020 
RRcalculated=2,47 [0,24-24,98] Not adjusted HCQ alone 
Supportive 
care 
Geleris et 
al(13), 2020 
HR=1,04 [0,82-1,32] inverse probability weighting from a propensity-score HCQ alone 
Standard care 
not specified 
Ip et al(31), 
2020 
HR=0.99 [0.8-1.22] 
HR=0.98 [0.75-1.28] 
Cox model adjusted on the propensity-score variable:  gender, coronary disease, stroke, heart 
failure, arrhythmia, African American, COPD, , renal failure, rheumatologic disorder, 
inflammatory bowel disease, advanced liver disease, age, diabetes mellitus, insulin use prior to 
hospitalization, asthma, HIV/hepatitis, any cancer, and log ferritin 
HCQ alone 
HCQ+AZ 
Group without 
drug 
Kuderer et 
al(10), 2020c 
OR=1,06 [0,51,2,2] 
OR=2.93 [1.79-4.79] 
Adjusted for age, sex, smoking status, and obesity 
HCQ alone 
HCQ+AZ 
Treatment 
without AZ 
Magagnoli et 
al(30), 2020 
HR=1.83 [1.16-2.89] 
HR=1.31 [0.80-2.15] 
Propensity score adjustment. All baseline covariates were included in the propensity score 
models (age, race, BMI, SpO2, breaths per minute, heart rate, T°, systolic blood pressure, ALT, 
AST, serum albumin, Total bilirubin, Creatinine, Erythrocytes, Haematocrit, Leukocytes, 
Lymphocytes, Platelets, Blood urea nitrogen, C-reactive protein 
HCQ alone 
HCQ+AZ 
Standard care 
Mahevas et 
al(11), 2020 
HR=1,2 [0,4,3,3] 
Inverse probability of treatment weighting in Cox model. age, sex, comorbidities (presence of 
chronic respiratory insufficiency during oxygen treatment, or asthma, cystic fibrosis, or any 
chronic respiratory disease likely to result in decompensation during a viral infection; heart 
failure (New York Heart Association class III or IV); chronic kidney disease; liver cirrhosis 
with Child-Pugh class B or more; personal history of cardiovascular disease (hypertension, 
stroke, coronary artery disease, or cardiac surgery); insulin dependent diabetes mellitus, or 
HCQ alone Standard care 
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diabetic microangiopathy or macroangiopathy; treatment with immunosuppressive drugs, 
including anticancer chemotherapy; uncontrolled HIV infection or HIV infection with CD4 cell 
counts <200/µL; or a haematological malignancy); body mass index (≥30 or not); third trimester 
of pregnancy; treatment by angiotensin converting enzyme inhibitors or angiotensin receptor 
blockers13; time since symptom onset; and severity of condition at admission (percentage of 
lung affected: ≥50% or not; presence of confusion; respiratory frequency; oxygen saturation 
without oxygen; oxygen flow; systolic blood pressure; and C reactive protein level). 
Membrillo et 
al(14), 2020 
OR=0,07 [0,012,0,402] Adjusted on variables with p<0,25in univariate analysis HCQ alone 
Standard care 
+ other 
antivirals, 
immunomodul
ators, anti-
inflammatory 
drugs 
Philippe 
Gautret et 
al(21), 2020 
RRcalculated =3,41 [0,1505,77,45] Not adjusted HCQ alone 
Group without 
HCQ 
RECOVERY 
TRIAL 
HR=1,1 [0,98,1,26] Adjustment not precised HCQ alone Standard care 
Rogado et 
al(35), 2020 
OR=0,02 [0,01,0,73] Adjusted by median age, histology, staging, cancer treatment received and hypertension HCQ+AZ 
Group without 
HCQ 
Rosenberg 
et al(16), 
2020 
HR=1,08 [0,63,1,85] 
HR=1.35 [0.76-2.4] 
Multiple adjustments on potential confounders (age>65, sex, hospital, comorbidities, respiratory 
capacities 
HCQ alone 
HCQ+AZ 
Group without 
drug 
Sanchez-
Alvarez et 
al(33), 2020 
OR=0,471 [0,28,0,792] No information about adjustments in logistic regression HCQ alone 
Standard care 
+ other 
antivirals 
Singh et 
al(36), 2020 
HR=0,95 [0,74,1,23] 
HR=1.19 [0.89-1.60] 
Creation of groups based on propensity score matching for age, gender, race, confounding 
comorbidities 
HCQ alone 
HCQ+AZ 
Group without 
HCQ 
Yu et al(12), 
2020 
HR=0,36 [0,18,0,75] 
Adjustment: respiratory rate, shortness of breath, alanine aminotransferase (when p<0,01 in 
univariate Cox model) 
HCQ alone Standard care 
Table 1 (continued): Characteristics of studies included in the meta-analysis for COVID-19 mortality 
IQ=Interquartile range, SD=Standard Deviation, HCQ=Hydroxychloroquine, AZ=Azithromycine, NA=Not available 
aSome studies did not report mean or median age 
bHR and OR are the most adjusted effect size reported in each study. Some studies did not report effect size. RRcalculated were calculated using the number of 
death in the treatment and the control groups 
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Study quality 250 
 251 
Risk of bias was assessed with ROBIN-I for non-randomised studies (n=14) and Rob2 was not 252 
applicable for RECOVERY RCT because data were not available (Figure S1). Details on the 253 
assessment of studies quality are provided in Fig S2. Among the non-randomized studies, the majority 254 
of these observational studies had a high or critical risk of bias (10 out of 16) 255 
(12,14,15,20,21,30,32,33,35,36). Five articles had a moderate risk of bias(10,11,13,16,31). Some 256 
studies did not report adjusted effect sizes to control confusion and selection bias (15,20,21,32,33,35). 257 
Studies quality was lowered by the lack of information about the assignment of treatment, the time 258 
between start of follow-up and start of intervention), some unbalanced co-intervention with other 259 
antiviral and antibiotic drugs. 260 
 261 
Hydroxychloroquine and mortality 262 
The pooled RR for COVID-19 mortality was 0.82 (95% CI: 0.62-1.07, I²=82, Pheterogeneity<0.01, n=15) 263 
(Figure 2) indicating no significant association between hydroxychloroquine and COVID-19 survival 264 
or increased mortality. There was significant high heterogeneity across the included studies (I² =83%, 265 
p<0.01). Egger's test (p= 0.42) and Begg's test (P=0.88) were not significant for asymmetry of the 266 
funnel plot indicating that there is not a major publication bias (Figure S3). In our separated analysis 267 
by study design, we found a positive but not significant association between hydroxychloroquine alone 268 
and mortality among interventional studies (RR: 1.10, 95%CI: 0.97-1.25, I²=0%, Pheterogeneity within=0.5, 269 
n=2); however an inverse but not significant association was found among observational studies (RR: 270 
0.78, 95%CI: 0.58-1.05, I²=82%, Pheterogeneity within <0.01), with heterogeneity observed across the study 271 
design (Pheterogeneity between = 0.03). 272 
 273 
 274 
 275 
 276 
 277 
 278 
 279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
 287 
 288 
 289 
 290 
 291 
 292 
 293 
 294 
 295 
 296 
 297 
 298 
 299 
 300 
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 301 
 302 
 303 
Figure 2: Meta-analysis showing association between hydroxychloroquine alone and COVID-19 304 
mortality. RCT=Randomised Controled Trial. nRCT=non-Randomised Controled Trial TE=Estimated 305 
treatment effect. seTE=Standard error of treatment estimate. RR=Risk ratio. RR were not adjusted for 306 
Alberici et al, Ayerbe et al, Barbosa et al, Sanchez-Alvarez et al and Gautret et al. 95%CI= 95% 307 
Confidence Interval 308 
 309 
 310 
 311 
 312 
Subgroup analysis for hydroxychloroquine alone  313 
Subgroup analysis among all studies (observational and interventional studies) per study design, type 314 
of article (peer-reviewed vs unpublished), risk estimated, age, the exclusion of cancer/haemodialysis 315 
patients identified a non-significant association in each subgroup (Table 2).  316 
 317 
 318 
 319 
 320 
 321 
 322 
 323 
 324 
 325 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted June 19, 2020. .https://doi.org/10.1101/2020.06.17.20133884doi: medRxiv preprint 
13 
 
 N Pooled Relative Risk Heterogeneity 
   I2 (%) P within Pbetween 
HCQ alone      
All Studies 15 0.82 [0.62-1.07] 82% <0.01  
Study Design      
Observational  13 0.78 [0.58-1.05] 82% <0.01 
0.03 
Interventional 2 1.10 [0.97-1.25] 0% 0.48 
Type of article      
Peer-reviewed 10 0.78 [0.53-1.16] 83% <0.01 
0.63 
Unpublished 5 0.88 [0.63-1.24] 74% <0.01 
Adjusted estimate      
Yes 9 0.91 [0.67-1.24] 70% <0.01 
<0.0001 
No 5 0.44 [0.35-0.56] 0% 0.41 
Missing 
1 1.10 [0.97-1.25] 
Not 
applicable 
Not 
applicable 
Risk estimated      
Reported in the paper 12 0.86 [0.66-1.12] 73% <0.01 
0.9 
Calculated  3 0.91 [0.21-3.93] 48% 0.14 
Risk of bias      
Moderate 5 1.02 [0.88-1.18] 0% 0.9 
0.19 Serious 6 0.63 [0.38-1.04] 89% <0.01 
Critical 3 0.97 [0.23-4.07] 31% 0.23 
      
Continents      
America 6 1.05 [0.93-1.19] 30% 0.2 
0.003 
Asia 1 0.36 [0.18-0.73] NA NA 
Europe 7 0.62 [0.41-0.93] 90% <0.01 
Multiple 1 1.06 [0.51-2.20] NA NA 
Mean daily dose      
Not specified 6 0.58 [0.39-0.85] 80% <0.01 
0.007 <500 mg/d 4 0.97 [0.55-1.69] 84% <0.01 
>500 mg/d 5 1.09 [0.98-1.22] 0% 0.88 
      
Age      
63 years or less 7 0.90 [0.65-1.26] 53% <0.05 
0.1 
64 years or more 7 0.69 [0.43-1.10] 88% <0.01 
Not specified  1 1.10 [0.97-1.07] NA NA  
Cancer or 
haemodialysis patient 
based-population 
     
No 12 0.87 [0.64-1.18] 84% <0.01 
0.26 
Yes 3 0.61 [0.35-1.06] 43% 0.17 
Influence analysis 
(exclusion of Yu et al, 
Magagnoli et al, 
Membrillo et al, 
Ayerbe et al) 
11 1.00 [0.90-1.12] 
29% 0.17  
HCQ+AZI      
All Studies 6 1.33 [0.91-1.91] 75% <0.01  
Study Design      
Observational  6 1.33 [0.91-1.91] 75% <0.01  
Interventional 0     
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Type of article      
Peer-reviewed 4 1.55 [0.86-2.80] 76% <0.01 
0.2 
Unpublished 2 1.07 [0.88-1.30] 0% 0.35 
Adjusted estimate      
Yes 6 1.33 [0.91-1.91] 75% <0.01 
 
No 0    
Risk estimated      
Reported in the paper 6 1.33 [0.91-1.91] 75% <0.01 
 
Calculated  0    
Risk of bias      
Moderate 3 1.54 [0.80-2.95] 86% <0.01 
0.06 Serious 2 1.22 [0.95-1.57] 0% 0.7 
Critical 1 0.02 [0.00-0.73] NA NA 
      
Continents      
America 3 1.10 [0.91-1.32] 0% 0.48 
0.0009 
Asia 0    
Europe 2 0.24 [0.00-13.43] 80% 0.02 
Multiple 1 2.93 [1.79-4.79] NA NA 
Mean daily dose      
Not specified 3 0.75 [0.08-7.21] 87% <0.01 
0.7 <500 mg/d 3 1.10 [0.87-1.38] 0% 0.43 
>500 mg/d 0    
Age      
63 years or less 2 1.22 [0.94-1.58] 0% 0.69 
0.9 64 years or more 4 1.30 [0.62-2.71] 85% <0.01 
      
Cancer or 
haemodialysis patient 
based-population 
     
No 6 1.33 [0.91-1.91] 75% <0.01 
 
Yes 0    
 326 
Table 2. Subgroup analysis for the associations between HCQ alone or HCQ associated with AZI and 327 
mortality risk of patients with COVID-19 (observational and interventional studies) 328 
N: number of studies. NA: Not applicable for a single study 329 
 330 
 331 
Test for subgroup differences (observational vs nRCT vs RCT) was not significant (P=0.09) 332 
suggesting no differences in the overall effect according to the design of the studies. The pooled RR 333 
for observational studies was 0.78 (95%CI: 0.58-1.05, I²=82%, Pheterogeneity within <0.01, n=13) and RR 334 
was 3.42 (95%CI: 0.15-77.20, n=1) for non-randomized controlled trial and 1.10 (95%CI: 0.97-1.25, 335 
n=1) for the RECOVERY randomized controlled trial (Figure 2). 336 
 337 
After stratification by the level of bias from ROBIN-I evaluation, the association between 338 
hydroxychloroquine and COVID-19 mortality remained non-significant. The broadness of 95% CI and 339 
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heterogeneity increased with the risk of bias: moderate risk of bias (RR=1.02 [0.88-1.18], I²=0, 340 
Pheterogeneity within =0.9, n=5), serious risk of bias (RR=0.63, 95% CI: (0.38-1.04, I²=89%, Pheterogeneity within 341 
<0.01, n=6)) and critical risk of bias (RR=0.97, 95% CI: (0.23-4.07, I²=31%, Pheterogeneity within =0.2, 342 
n=3)) (Figure S4).  343 
 344 
In our stratified analysis by continents (Figure S5), interestingly, we found a significant decreased risk 345 
of mortality with HCQ alone among Asian (RRAsia=0.36, 95%CI: 0.18-0.73, n=1) and European 346 
studies (RREurope=0.62 (95%CI: 0.41-0.93, I²=90%, Pheterogeneity within <0.01, n=7)) but there was no 347 
significant association among American studies, with heterogeneity detected across continent 348 
(Pheterogeneity between=0.003).  349 
 350 
Furthermore, we found no association between HCQ alone and mortality by HCQ daily mean dose. 351 
The pooled RR was 1.09 (95%CI: 0.98-1.22, I²=0%, Pheterogeneity within=0.9, n=5), for studies with 352 
>500mg, (RR=0.97 (95%CI: 0.55-1.69, I²=84%, Pheterogeneity within<0.01, n=4) for HCQ dose<500 mg 353 
and (RR=0.58 (95%CI: 0.39-0.85, I²=80%, Pheterogeneity within<0.01, n=6) for an unspecified dose of 354 
HCQ, with heterogeneity detected across HCQ dose categories (Pheterogeneity between=0.007). 355 
 356 
In our stratified analysis by studies which reported adjusted effect sizes (vs non-adjusted), the pooled 357 
RR for adjusted estimates was RR=0.91 (95%CI: 0.67-1.24, I²=70%, Pheterigeneity within<0.01, n=9) and 358 
for non-adjusted estimates RR=0.44 (95%CI: 0.35-0.56, I²=0%, Pheterigeneity within<0.41, n=5), suggesting 359 
differences in the overall effect according to the presence of adjustment on potential confounders.  360 
 361 
Influence analysis showed that Yu et al, Membrillo et al, Ayerbe et al, Magagnoli et al are influent 362 
studies (Figure S7). Removing these studies make heterogeneity decrease at I²=0% but the results 363 
remained non-significant (RR=1.00 (95% CI: 0.0-1.13, I²=29%, n=11) (Table 2). 364 
 365 
All the results remained similar after exclusion of the two interventional studies (Table S1). 366 
 367 
Hydroxychloroquine with azithromycin and mortality 368 
The pooled RR for COVID-19 mortality was 1.33 (95% CI: 0.91-1.921, n=6) (Figure 3) indicating no 369 
significant association between hydroxychloroquine with azithromycin and survival. There was 370 
significant high heterogeneity across the included studies (I² =75%, p<0.01). Egger's test (p= 0.9) and 371 
Begg's test (p=0.6) were not significant but the asymmetry in the funnel plot indicates that there could 372 
be a publication bias. However, the number of included studies is small. 373 
 374 
 375 
Figure 3: Meta-analysis showing association between hydroxychloroquine with azithromycin and 376 
COVID-19 mortality. TE=Estimated treatment effect. seTE=Standard error of treatment estimate. 377 
RR=Risk ratio. 95%CI= 95% Confidence Interval 378 
 379 
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Subgroup analysis for hydroxychloroquine with azithromycin  380 
In all the subgroup analysis (type of article, effect size, risk of bias, continent, mean daily dose, age, 381 
exclusion of cancer and haemodialysis patients, influence analysis), no significant association between 382 
hydroxychloroquine with azithromycin and mortality was found (Table 2). Nevertheless, in our 383 
stratified analysis by continents, we found no significant association with COVID-19 survival risk 384 
among American studies (RR=1.10, 95%CI: 0.91-1.32, I²=0%, Pheterogeneity within=0.48, n=3) and 385 
European studies (RR=0.24 (95%CI: 0.00-13.43, I²=80%, Pheterogeneity within <0.02, n=2)) but there was a 386 
significant increased risk of mortality in the multiple countries (RR=2.93, 95%CI: 1.79-4.79, n=1), 387 
with heterogeneity detected across continent (Pheterogeneity between=0.0009).  388 
 389 
 390 
Discussion 391 
This meta-analysis summarized the results of 14 observational studies, 1 non-randomised study and 1 392 
unpublished randomised controlled trial on hydroxychloroquine with or without azithromycin and 393 
COVID-19 survival (Table 1). The results indicated that hydroxychloroquine with or without 394 
azithromycin is ineffective to reduce COVID-19 mortality risk in hospitalized patients (Figure 2 and 395 
3). Eight observational studies reported no advantage for hydroxychloroquine 396 
(10,11,13,16,20,21,31,32). One US Veterans study identified an increased risk of death(30). Three 397 
Spanish and one Chinese studies reported a protective effect (12,14,15,33) but this benefit on survival 398 
was not replicated in two RCT, especially RECOVERY Trial which is one of the largest study. Our 399 
meta-analysis reported a high heterogeneity. The use of an adjusted effect size to control confusion 400 
bias, the daily HCQ dose, the risk of bias and the localisation of the study (by continents) may explain 401 
one part of the heterogeneity observed according to our subgroup analysis. 402 
 403 
Subgroup analysis revealed that there was a decreased risk of death among 6 European non-404 
randomised studies, one observation Asian study and for studies which did not specify the treatment 405 
dose. However, five (14,15,21,32,33) of these European studies have a serious or critical risk of bias 406 
(Figure S1). This significant relationship could be explained by a high risk of confusion bias since 407 
these articles did not reported adjusted effect size. These studies also have several biases, such as a 408 
selection bias Gautret et al, control and treatment groups did not come from the same hospital. In 3 409 
Spanish studies (14,15,33), there was no information when treatment were administrated and when the 410 
follow-up began which may lead to a bias in selection. Studies with an adjusted HR in figure S5 and 411 
with a higher quality reported a non-significant higher RR than the other studies. In this meta-analysis, 412 
the majority of the included studies had a high or critical risk of bias (10 out of 16) (Figure S1 and S2). 413 
Most of them do not always report the concomitant use of antiviral or antibacterial drugs. In our 414 
subgroup analysis by study design, we found inconsistent results with a positive but not significant 415 
association between hydroxychloroquine alone and mortality among interventional studies and an 416 
inverse but not significant association among observational studies (Table 2). Heterogeneity between 417 
these subgroups was observed across the study design. However, these findings are limited by the very 418 
low number of interventional studies. 419 
 420 
Two Chinese randomised controlled trial reported no death in both treatment and control group 421 
(38,39) and thus their results were not included in our meta-analysis. A previous review on 8 studies 422 
(11–14,20,30,39,40) on COVID-19 concluded that the level of evidence for hydroxychloroquine effect 423 
is very weak(41). A preprint meta-analysis, using routinely collected records from clinical practice in 424 
Germany, Spain, the UK, Japan, and the USA, compared the use of HCQ vs salfasalazine (42). This 425 
study observed an increased risk of 30-day cardiovascular mortality (HR=2.19 [1.22-3.94]) but there 426 
was no standard care comparative group. Some previous meta-analyses were also conducted on 427 
hydroxychloroquine and various health endpoints including mortality. However these studies did not 428 
report all the published and unpublished literature, including a very limiting number of studies: from 3 429 
articles(17,18) to 6 articles(19). These previous meta-analyses did not perform subgroup and 430 
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sensitivity analysis to test the effect of pooling RCT and observational study, neither studying the 431 
source of heterogeneity. They used unadjusted risk ratio (calculated with the number of events in each 432 
group) whereas in our meta-analysis, we used adjusted relative risk (43) and we did sensitivity 433 
analysis on the adjustment of effect size. Statistical adjustments for key prognostic variables allow to 434 
limit confusion bias, especially in observational studies which are not randomised. Our meta-analysis 435 
confirmed the partial preliminary results of these meta-analyses about the absence of effect for HCQ 436 
on survival. 437 
 438 
Our study has several strengths. To our knowledge, this is the first meta-analysis using adjusted 439 
relative risk and including numerous subgroup analysis (by continent, population age, effect size, risk 440 
of bias, published articles, mean daily dose of hydroxychloroquine, exclusion of cancer and 441 
haemodialysis patients) which found stable and consistent results. This study informs clinicians and 442 
patients regarding the efficiency of HCQ in treating COVID-19. We included several unpublished 443 
papers to minimize the publication bias. Our subgroup analysis by published studies (vs unpublished 444 
studies) identified that the inclusion of preprints did not change the results. Exclusion of grey literature 445 
(unpublished studies, with limited distribution) could lead to an exaggeration of the intervention effect 446 
by 15% (44). There is limited evidence to identify whether grey studies have a poorer methodological 447 
quality than published studies(45). Mortality is a reliable endpoint across studies. Limitations come 448 
from the studies which do not report adjusted effect size when mortality was not the primary endpoint. 449 
Confounding bias is high in these articles (mainly for the preprints). This meta-analysis was based on 450 
aggregated data, without access to original patient data. Most of studies are observational which do not 451 
allow to identify a causal association. This meta-analysis did not include results from the European 452 
DISCOVERY trial and the WHO SOLIDARITY trial (46). To finish, some of the included studies had 453 
very low quality of evidence (missing data, small sample size, confusion bias, bias in classification of 454 
intervention and selection bias) but the exclusion of these articles did not change the results. 455 
 456 
Few peer-reviewed studies with a comparative group analysed some other endpoints such as 457 
virological clearance, clinical improvement and arrhythmia risks. A recent randomized controlled trial 458 
with 821 asymptomatic participants in contact with a COVID-19 confirmed case, concluded 459 
hydroxychloroquine was not efficient to prevent illness in a prophylactic way (47).  However, this trial 460 
had a limitation: only 16 participants had a confirmed positive RT-PCR test. A small French non-461 
randomised trial identified a higher proportion of negative RT-PCR tests in the HCQ group (21) but 462 
two other RCT did not find any difference between the HCQ and standard care groups for clinical 463 
improvement (38,39). 464 
 465 
Several studies raised concerns about an increase of the QTc interval with HCQ use in an intensive 466 
care unit (48) and hospitalized patients (11,49). However, this side effect was not found in Tang et al. 467 
RCT. Several national health organisations (US FDA Food and Drug Administration(50), French 468 
Agency for the Safety of Health Products ANSM (51), European Medecine Agency EMA(52)) raised 469 
concerns about using this unapproved drug for COVID-19. ANSM et US FDA removed the 470 
authorization for its use outside of clinical trials. The Indian Council of Medical Research took an 471 
opposite position and recommend chemoprophylaxis with hydroxychloroquine for asymptomatic cases 472 
(53). In an open label, randomised controlled trial with hydroxychloroquine in patient with mild and 473 
moderate symptoms, no death were reported (38). Finally, in the comparative peer-reviewed studies, a 474 
clear conclusion on hydroxychloroquine is not possible due to the small sample size, the lack of well-475 
performed randomised controlled trials (mainly non-randomised and retrospective studies) and 476 
inconsistent results. Many preprints without comparative group and without randomization bring 477 
confusion in this highly politicised topic. There is a gap between the speed of clinical research and the 478 
expectation of a clear solution to treat COVID-19 patients. Indeed, producing robust clinical trials is 479 
necessarily time-consuming. Results from large RCT are needed to shut down the controversy.  480 
 481 
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 482 
 483 
Conclusion 484 
In conclusion, there is no strong evidence supporting a benefice for hydroxychloroquine with or 485 
without azithromycin to improve survival of COVID-19 hospitalized patients. Conversely, there is no 486 
strong evidence supporting an increased mortality associated with HCQ or HCQ + AZ intake. 487 
 488 
 489 
 490 
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OR death) 874 
 875 
Web of Science 876 
Website: 877 
http://apps.webofknowledge.com.proxy.insermbiblio.inist.fr/Search.do?product=UA&SID=F6KgcWI878 
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S2. PRISMA Checklist 903 
 904 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-
analysis, or both.  
p.1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as 
applicable: background; objectives; data sources; 
study eligibility criteria, participants, and 
interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and 
implications of key findings; systematic review 
registration number.  
p.2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the 
context of what is already known.  
p.3 
Lines 110-138 
Objectives  4 Provide an explicit statement of questions being 
addressed with reference to participants, 
interventions, comparisons, outcomes, and study 
design (PICOS).  
p.3 
Lines 139-141 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where 
it can be accessed (e.g., Web address), and, if 
available, provide registration information 
including registration number.  
3 
Line 154 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length 
of follow-up) and report characteristics (e.g., 
years considered, language, publication status) 
used as criteria for eligibility, giving rationale.  
p.4 
Lines 170-187 
Information sources  7 Describe all information sources (e.g., databases 
with dates of coverage, contact with study authors 
to identify additional studies) in the search and 
date last searched.  
p.3 
Lines 146-152 
Search  8 Present full electronic search strategy for at least 
one database, including any limits used, such that 
it could be repeated.  
p.3 lines 147-152 
p.29   S1.  
Study selection  9 State the process for selecting studies (i.e., 
screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-
analysis).  
p.4 lines 159-164 
Data collection process  10 Describe method of data extraction from reports 
(e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming 
data from investigators.  
p.4 lines 166-169 
Data items  11 List and define all variables for which data were 
sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
p.4 lines 170-186 
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias 
of individual studies (including specification of 
whether this was done at the study or outcome 
level), and how this information is to be used in 
any data synthesis.  
p.4 lines 184-186 
Summary measures  13 State the principal summary measures (e.g., risk 
ratio, difference in means).  
p.4 lines 171-183 
Synthesis of results  14 Describe the methods of handling data and 
combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-
analysis.  
p.4-5 
lines 
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may 
affect the cumulative evidence (e.g., publication 
bias, selective reporting within studies).  
p.4 line 202-203 
Additional analyses  16 Describe methods of additional analyses (e.g., 
sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-
specified.  
p.5 lines 208-218 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for 
eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow 
diagram.  
p.5 
Fig. 1 
Study characteristics  18 For each study, present characteristics for which 
data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
p. 6-10 
Table 1 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if 
available, any outcome level assessment (see item 
12).  
p.23 
Supplemantary 
Figures S1 and S2 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), 
present, for each study: (a) simple summary data 
for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
5-7 
Synthesis of results  21 Present results of each meta-analysis done, 
including confidence intervals and measures of 
consistency.  
p.11-16 
Fig.2-3 
Table 2 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias 
across studies (see Item 15).  
p.11 lines 266-273 
p.15 lines 371-374 
Figure S3 
Additional analysis  23 Give results of additional analyses, if done (e.g., 
sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
p.13-15 Lines 313-
367 
p.16 lines 381-389 
Table S1 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength 
of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, 
users, and policy makers).  
p.16 lines 393-437 
Limitations  25 Discuss limitations at study and outcome level 
(e.g., risk of bias), and at review-level (e.g., 
p.17 lines 439-454 
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incomplete retrieval of identified research, 
reporting bias).  
Conclusions  26 Provide a general interpretation of the results in the 
context of other evidence, and implications for 
future research.  
P.17 lines 465-486 
FUNDING   
Funding  27 Describe sources of funding for the systematic 
review and other support (e.g., supply of data); role 
of funders for the systematic review.  
Funding 
information is 
entered in the 
financial disclosure 
section of the 
submission system 
 905 
 906 
Table S1: Subgroup analysis for the associations between HCQ+AZI and mortality risk of 907 
patients with COVID-19 (observational studies) 908 
Subgroup analysis for the associations between HCQ and mortality risk of patients with 
COVID-19 (excluding interventional studies) 
 N RRpooled Heterogeneity 
   I2 (%) P within Pbetween 
HCQ alone      
All Studies 13     
Type of article      
Peer-reviewed 9 0.76 [0.51-1.13] 85% <0.01 
0.84 
Unpublished 4 0.81 [0.52-1.27] 72% 0.01 
Adjusted estimate      
Yes 9 0.91 [0.67-1.24] 70% <0.01 
0.0001 
No 4 0.44 [0.35-0.55] 0% 0.52 
Risk estimated      
Reported in the paper 11 0.83 [0.61-1.11] 72% <0.01 
0.82 
Calculated  2 0.69 [0.15-3.25] 54% 0.14 
Risk of bias      
Moderate 5 1.02 [0.88-1.18] 0% 0.9 
0.18 Serious 6 0.63 [0.38-1.04] 89% <0.01 
Critical 2 0.75 [0.16-3.58] 44% 0.18 
      
Continents      
America 6 1.05 [0.93-1.19] 30% 0.2 
<0.0001 
Asia 1 0.36 [0.18-0.73] NA NA 
Europe 5 0.45 [0.37-0.55] 0% 0.47 
Multiple 1 1.06 [0.51-2.20] NA NA 
Mean daily dose      
Not specified 6 0.58 [0.39-0.85] 80% <0.01 
0.029 <500 mg/d 4 1.06 [0.84-1.33] 0% 0.75 
>500 mg/d 3 0.58 [0.39-0.85] 80% <0.01 
      
Age      
63 years or less 6 0.89 [0.64-1.24] 59% 0.03 
0.39 
64 years or more 7 0.69 [0.43-1.10] 89% <0.01 
      
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted June 19, 2020. .https://doi.org/10.1101/2020.06.17.20133884doi: medRxiv preprint 
34 
 
Cancer or 
hemodialysis patient 
based-population 
     
No 10 0.83 [0.59-1.18] 85% <0.01 
0.34 
Yes 3 0.61 [0.35-1.06] 43% 0.17 
Influence analysis 
(exclusion of Yu et al, 
Magagnoli et al, 
Membrillo et al, 
Ayerbe et al) 
9 0.95 [0.84-1.08] 27% 0.20  
 909 
 910 
 911 
 912 
 913 
 914 
 915 
 916 
 917 
 918 
 919 
 920 
 921 
 922 
 923 
 924 
 925 
 926 
 927 
 928 
 929 
 930 
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